This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization
Clinical trial NCT07587658 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07587658
- Sponsor
- Regeneron Pharmaceuticals
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-30
- Primary completion
- 2028-07-30
- Enrollment
- 754
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.